TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30221961

Group type: EXPERIMENTAL
Intervention: Foster care intervention (removal from institutions and placement into a family)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (remaining in institutions)
Number of subjects: 0
Study: 29018897

Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urate addition in RAW264.7 cell osteoclastogenesis assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urate addition in primary cell osteoclastogenesis or resorption assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urate addition in MC3T3‐E1 pre‐osteoblast, primary human osteoblast, or MLO‐Y4 osteocyte assays
Number of subjects: 0
Study: 27206549

Group type: EXPERIMENTAL
Intervention: Arabinoxylan-oligosaccharide (AXOS) 4 × 9.4 g
Number of subjects: 13

Group type: COMPARATOR
Intervention: Maltodextrin (placebo) 4 × 10 g
Number of subjects: 13
Study: 24529258

Group type: EXPERIMENTAL
Intervention: Intervention group (24 schools, 1,222 pupils)
Number of subjects: 1939

Group type: COMPARATOR
Intervention: Control group (14 schools, 717 pupils)
Number of subjects: 1939

Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 1939

Group type: EXPERIMENTAL
Intervention: Fast-food consumption
Number of subjects: 1939
Study: 19104205

Group type: EXPERIMENTAL
Intervention: Glycerin payayor, a Thai prepared herbal product, used 3 times a day from the first to the last day of radiation.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Benzydamine hydrochloride, rinsed 3 times a day from the first to the last day of radiation.
Number of subjects: 60
Study: 16398424

Group type: EXPERIMENTAL
Intervention: Sijunzi decoction (SJZD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (isocaloric and isonitrogenous enteral nutritional support only)
Number of subjects: 92
Study: 11756368

Group type: EXPERIMENTAL
Intervention: Medical abortion (mifepristone 200 mg followed by misoprostol up to 3 doses)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Surgical abortion (vacuum aspiration under general anaesthesia)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Medical abortion
Number of subjects: 188

Group type: COMPARATOR
Intervention: Surgical abortion
Number of subjects: 188
Study: 9230252

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1 mg of nicotine per 100 microL)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 157
Study: 7895421

Group type: EXPERIMENTAL
Intervention: Fasting with no fluid replacement
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fasting with salt and water supplementation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fasting with fluid restriction
Number of subjects: 15
Study: 3294614

Group type: EXPERIMENTAL
Intervention: Captopril at a dose of 25 mg twice a day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Nadolol at a dose of 80 mg once a day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Frusemide at a dose of 25 mg once a day
Number of subjects: 74
Study: 31666833

Group type: EXPERIMENTAL
Intervention: Taurine (TN) and meldonium (ME)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (GoC)
Number of subjects: 98
Study: 29410479

Group type: EXPERIMENTAL
Intervention: High protein and low glycemic index diet (n=38)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 76
Study: 26926680

Group type: EXPERIMENTAL
Intervention: TriMixDC-MEL plus ipilimumab
Number of subjects: 39
Study: 24106141

Group type: EXPERIMENTAL
Intervention: Cadazolid (30 mg to 3000 mg, twice daily for 10 days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cadazolid (300 mg, single dose)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cadazolid (multiple doses)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 22800086

Group type: EXPERIMENTAL
Intervention: High-dose antioxidant tablets
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 58
Study: 20849868

Group type: EXPERIMENTAL
Intervention: Protein shake (AUC=37,024±3518nmol/L min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fat shake (AUC=35,977±3562nmol/L min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate shake (AUC=47,310±3667nmol/L min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (control condition) (AUC=32,784±1683nmol/L min)
Number of subjects: 10
Study: 17826370

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3941

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3941
Study: 15606521

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 50
Study: 11473863

Group type: EXPERIMENTAL
Intervention: Early reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 2 min after 1.5 mg/kg rapacuronium
Number of subjects: 119

Group type: COMPARATOR
Intervention: Late reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 25% T1 recovery after 1.5 mg/kg rapacuronium
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Early reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 2 min after 2.0 mg/kg rapacuronium
Number of subjects: 119

Group type: COMPARATOR
Intervention: Late reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 25% T1 recovery after 2.0 mg/kg rapacuronium
Number of subjects: 119
Study: 9550847

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7825998

Group type: EXPERIMENTAL
Intervention: Methylprednisolone at 30 mg/kg i.v. for 3 days followed by 20 mg/kg for 4 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment group
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment
Number of subjects: 8
Study: 3387687

Group type: EXPERIMENTAL
Intervention: Tartrazine (up to 25 mg)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Tartrazine (50-3,000 mg)
Number of subjects: 156
Study: 30203029

Group type: COMPARATOR
Intervention: SMEDS‐EPA
Number of subjects: 80

Group type: COMPARATOR
Intervention: SMEDS‐DHA
Number of subjects: 80

Group type: COMPARATOR
Intervention: EE‐EPA
Number of subjects: 80

Group type: COMPARATOR
Intervention: EE‐DHA
Number of subjects: 80

Group type: COMPARATOR
Intervention: SMEDS
Number of subjects: 80
Study: 28222531

Group type: EXPERIMENTAL
Intervention: Physical exercise with music (ExM)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cognitive stimulation (CS)
Number of subjects: 85
Study: 26129947

Group type: EXPERIMENTAL
Intervention: Routine manual thrombectomy
Number of subjects: 10732
Study: 23324112

Group type: EXPERIMENTAL
Intervention: Group V-CTC (vacuum‐formed retainer in the maxilla and bonded canine‐to‐canine retainer in the mandible)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group V-S (vacuum‐formed retainer in the maxilla combined with stripping of the 10 proximal surfaces of the lower mandibular anterior teeth)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group P (prefabricated positioner covering the teeth in the maxilla and the mandible)
Number of subjects: 75
Study: 20947241

Group type: EXPERIMENTAL
Intervention: 30:2 compression:ventilation ratio
Number of subjects: 42

Group type: COMPARATOR
Intervention: 15:2 compression:ventilation ratio
Number of subjects: 42
Study: 18315686

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 3182

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 3182
Study: 17111685

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 150
Study: 14633567

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with thoracic epidural anesthesia (TEA) (group E, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anesthesia (group G, n = 10)
Number of subjects: 20
Study: 11156449

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conventional open diathermy technique
Number of subjects: 119
Study: 9174298

Group type: EXPERIMENTAL
Intervention: Bupivacaine (3-10 mL of 0.25%-0.5%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8478309

Group type: EXPERIMENTAL
Intervention: Dirithromycin (500 mg, two tablets once daily)
Number of subjects: 7437

Group type: COMPARATOR
Intervention: Comparator antibiotics (1000 mg erythromycin base, 300 mg roxithromycin, 1200 mg miocamycin)
Number of subjects: 7437

Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 7437

Group type: COMPARATOR
Intervention: Comparator antibiotics
Number of subjects: 7437
Study: 3709640

Group type: EXPERIMENTAL
Intervention: 150 mg disopyramide i.v.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 7.5 mg atenolol i.v.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both disopyramide and atenolol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Disopyramide and atenolol (combined use)
Number of subjects: 7
Study: 31591483

Group type: EXPERIMENTAL
Intervention: High satiety responsive group (HighSR)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High food responsive group (HighFR)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High emotional eating group (HighEE)
Number of subjects: 150
Study: 29262271

Group type: EXPERIMENTAL
Intervention: C7 nerve transfer plus rehabilitation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 36
Study: 27073145

Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal tablet 500 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Oral fluconazole 150 mg
Number of subjects: 240
Study: 24801283

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg prasugrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 180 mg ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23102968

Group type: EXPERIMENTAL
Intervention: 9-phage cocktail at a dose of 3×10(9) plaque-forming units
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 9-phage cocktail at a dose of 3×10(7) plaque-forming units
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 9-phage cocktail (both doses)
Number of subjects: 15
Study: 20233175

Group type: EXPERIMENTAL
Intervention: 'Get Randomised' media campaign (television, radio, newspaper advertising)
Number of subjects: 1040
Study: 18613991

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (specialty advice and evidence-based messages regarding medication management for cardiovascular risk)
Number of subjects: 639

Group type: COMPARATOR
Intervention: Control (no intervention, received e-mail with periodic generic information about cardiovascular risk reduction in diabetes)
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 639
Study: 16182898

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 418

Group type: COMPARATOR
Intervention: Nitrogen
Number of subjects: 418
Study: 11927130

Group type: EXPERIMENTAL
Intervention: Subcutaneous unfractionated heparin (UH) administered in two to three subcutaneous doses adjusted to activated partial thromboplastin time (APTT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) (dalteparin) administered in a fixed dose of 200 IU/kg body weight in one subcutaneous injection daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both groups (UH and LMWH)
Number of subjects: 59
Study: 10440622

Group type: COMPARATOR
Intervention: Skim milk
Number of subjects: 23

Group type: COMPARATOR
Intervention: High-fat breakfast
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fasted conditions
Number of subjects: 23
Study: 7589047

Group type: EXPERIMENTAL
Intervention: Nicotine vapour inhaler
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 15
Study: 2085330

Group type: EXPERIMENTAL
Intervention: Hemodialysate (Solcoseryl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 383851

Group type: EXPERIMENTAL
Intervention: Ro 20-1724
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.025% triamcinolone acetonide (intensive occlusive treatment)
Number of subjects: 0
Study: 30979042

Group type: EXPERIMENTAL
Intervention: Low-Intensity Cognitive Behavior Therapy (LI-CBT) mHealth-supported intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WhatsApp usage during the intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LI-CBT intervention at 1-month follow-up
Number of subjects: 0
Study: 28326906

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) tablets
Number of subjects: 0
Study: 25602615

Group type: EXPERIMENTAL
Intervention: Conventional English-as-a-second-language (ESL) instruction
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 155
Study: 23348400

Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Nutrient restriction early during critical illness
Number of subjects: 280
Study: 21268101

Group type: EXPERIMENTAL
Intervention: Trospium XR 60 mg once daily for 12 weeks
Number of subjects: 1165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1165
Study: 18955519

Group type: COMPARATOR
Intervention: BILR 355 coadministered with 100 mg ritonavir (RTV) at doses of 5 to 50 mg in a polyethylene glycol solution or 50 to 250 mg as tablets, and 150 mg BID coadministered with 100 mg RTV QD or BID.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17418559

Group type: EXPERIMENTAL
Intervention: 7‐Keto
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HUM5007
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16127251

Group type: EXPERIMENTAL
Intervention: SVD-CBF without correction for tracer delay
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: SVD-CBF with correction for tracer delay
Number of subjects: 7

Group type: COMPARATOR
Intervention: PET-CBF
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tracer delay in white matter
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tracer delay in gray matter
Number of subjects: 7
Study: 11511131

Group type: EXPERIMENTAL
Intervention: Free-report conditions allowing children to monitor and control their answers.
Number of subjects: 3
Study: 9242943

Group type: EXPERIMENTAL
Intervention: Traditional dialysis using dialyzers with a urea clearance of 170‐180 ml/min
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: All hemodialysis treatments
Number of subjects: 195
Study: 8333759

Group type: EXPERIMENTAL
Intervention: Withholding cows' milk protein during the first three months of life
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 453

Group type: COMPARATOR
Intervention: Control group (not breast fed)
Number of subjects: 453
Study: 3567113

Group type: EXPERIMENTAL
Intervention: High alcohol condition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low alcohol condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall alcohol effect
Number of subjects: 60
Study: 2598970

Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine (D3 nicardipine)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous unlabelled nicardipine (D0 nicardipine)
Number of subjects: 6
Study: 30972654

Group type: EXPERIMENTAL
Intervention: Discrete Trial Training (DTT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pivotal Response Training (PRT)
Number of subjects: 0
Study: 28279316

Group type: EXPERIMENTAL
Intervention: COMBO Dual Therapy Stent
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cobalt-Chromium Everolimus-Eluting Stent (CoCr EES)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 25998206

Group type: EXPERIMENTAL
Intervention: 50 mg milnacipran twice daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 23040140

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 163
Study: 21744962

Group type: EXPERIMENTAL
Intervention: Couples intervention
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Individual diabetes education
Number of subjects: 44
Study: 18754014

Group type: EXPERIMENTAL
Intervention: Enteral sterile water (up to 50 ml kg(‐1) per day for 7 days)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Routine fluid management (control group)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Enteral sterile water
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 214
Study: 16411579

Group type: EXPERIMENTAL
Intervention: Flow diagram of an RCT as a pedagogic aid
Number of subjects: 0
Study: 15317632

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy for insomnia (5 sessions, 7 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-help manual with telephone support (5 calls, 7 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-help treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Regular users of sedative medication at baseline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural strategies
Number of subjects: 60
Study: 10890311

Group type: COMPARATOR
Intervention: Haloperidol 2 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amisulpride 200 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9058177

Group type: EXPERIMENTAL
Intervention: Anger-out (described loudly and quickly)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anger-in (relived inwardly)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mood-incongruent speech (described softly and slowly)
Number of subjects: 24
Study: 8398006

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 29617851

Group type: EXPERIMENTAL
Intervention: Factor D (selenium/vitamin E/beta‐carotene)
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: Factor B (riboflavin/niacin)
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: Factor A (retinol/zinc)
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: Factor C (vitamin C/molybdenum)
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: Factors C and D
Number of subjects: 29584
Study: 28898959

Group type: EXPERIMENTAL
Intervention: Cognitive training using a novel memory game on an iPad (n=21; 8 hours of gameplay over 4 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cognitive training using a novel memory game on an iPad
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n=21; clinic visits as usual)
Number of subjects: 42
Study: 26210642

Group type: EXPERIMENTAL
Intervention: ISIS‐APO(a)Rx 100 mg (6 doses)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ISIS‐APO(a)Rx 200 mg (6 doses)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ISIS‐APO(a)Rx 300 mg (6 doses)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (6 doses)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ISIS‐APO(a)Rx (single doses 50-400 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (single doses)
Number of subjects: 47
Study: 23011409

Group type: EXPERIMENTAL
Intervention: CoQ(10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline Solution (SS)
Number of subjects: 40
Study: 20625691

Group type: EXPERIMENTAL
Intervention: Transplantation of mononuclear bone marrow cells (MBMC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ACE genotype II
Number of subjects: 48

Group type: COMPARATOR
Intervention: Matrix metalloproteinase‐2 triple genotype GGCCTT
Number of subjects: 48

Group type: COMPARATOR
Intervention: I/D ACE polymorphism
Number of subjects: 48
Study: 18202564

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Training (HIT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Repeated Sprint (RS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both HIT and RS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HIT
Number of subjects: 15
Study: 17199209

Group type: EXPERIMENTAL
Intervention: Fluoride varnish Fluoridin N5 (VOCO GmbH) applied every 6 months for 2 years
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Duraphat (Colgate Palmolive GmbH) applied every 6 months for 2 years
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no fluoride varnish applications)
Number of subjects: 200
Study: 12723759

Group type: EXPERIMENTAL
Intervention: Goshajinkigan, 7.5 g/day for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo, 6.0 g/day for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Goshajinkigan, 7.5 g/day for 3 months (in non-diabetic subjects)
Number of subjects: 50
Study: 10071469

Group type: EXPERIMENTAL
Intervention: Sandwich technique with resin‐modified glass‐ionomer cements
Number of subjects: 120

Group type: COMPARATOR
Intervention: Base technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Total bond technique
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sandwich technique with compomers
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vitremer/Z100 sandwich restorations with a metal matrix
Number of subjects: 120
Study: 7484484

Group type: EXPERIMENTAL
Intervention: Oxybutynin plus bladder training
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo plus bladder training
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57